Dolutegravir Sodium CAS NO1051375-19-9

Product Description:

Product Name: Dolutegravir Sodium CAS NO:1051375-19-9

Synonyms:

Sodium (4R,12aS)-9-((2,4-difluorobenzyl)carbamoyl)-4-methyl-6,8-dioxo-3,4,6,8,12,12a-hexahydro-2H-pyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazin-7-olate;

sodium,(4R,12aS)-9-[(2,4-difluorophenyl)methylcarbamoyl]-4-methyl-6,8-dioxo-3,4,12,12a-tetrahydro-2H-pyrido[5,6]pyrazino[2,6-b][1,3]oxazin-7-olate;

(4R,12aS)-N-(2,4-difluorobenzyl)-7-hydroxy-4-methyl-6,8-dioxo-3,4,6,8,12,12a-hexahydro-2H-pyrido[1',2':4,5]pyrazino-[2,1-b][1,3]oxazine-9-carboxamide sodium salt;

Chemical & Physical Properties:

Appearance :pale yellow powder

Assay :≥99.0%

Dolutegravir Sodium is a second-generation HIV-1 integrase chain transfer inhibitor. Dolutegravir Sodium is currently in a phase III clinical trial for the treatment of HIV infection. It has been shown that Dolutegravir Sodium can effectively inhibit HIV replication in cells infected with the inactivated PHIV lentiviral vector, such as peripheral blood mononuclear cells (PBMC), MT-4 cells and CIP4 cells.

If you are interested in our products or have any questions, please feel free to contact us!

Products under patent are offered for R & D purpose only. However, the final responsibility lies exclusively with the buyer.